Home    Back

Alpha-tocopherol    (DrugBank: alpha-tocopherol, Tocopherol)

2 diseases
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus1
206Fragile X syndrome1

49. Systemic lupus erythematosus    [ 827 clinical trials,   638 drugs,   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways]
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 827 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-004404-21-GB
(EUCTR)		10/12/200417/02/2005Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in LupusOmega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus Systemic Lupus ErythematosusTrade Name: Omacor
Product Name: Omacor
INN or Proposed INN: Eicosapentaenoic acid
INN or Proposed INN: Docosahexaenoic acid
INN or Proposed INN: alpha-tocopherol		GreenPark Healthcare TrustQueens University BelfastNot RecruitingFemale: yes
Male: yes		60Phase 4United Kingdom

206. Fragile X syndrome    [ 98 clinical trials,   73 drugs,   (DrugBank: 27 drugs),   46 drug target genes,   57 drug target pathways]
Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 98 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01329770
(ClinicalTrials.gov)		December 201029/3/2011Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X SyndromePhase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X SyndromeFragile X SyndromeDietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: PlaceboYolanda de Diego OteroNULLCompleted6 Years18 YearsMale30Phase 2Spain